Lipid Therapeutics GmbH aims to extend its pivotal program for its ulcerative colitis treatment LT-02 into the U.S., following an investigational new drug grant from the FDA that will enable it and its partner, Dr. Falk Pharma GmbH, to conduct a joint Phase III program on either side of the Atlantic. The plan depends on the company finding a U.S. partner, however.